bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S2 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: November 2024

Supplementary Table S2. Small molecule inhibitors used.
Supplementary Table S1 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: November 2024

Supplementary Table S1. Drugs, chemicals, and reagents used.
Supplementary Figure S5 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: November 2024

Supplementary Figure S5. Effect of BRAF and CRAF KO on MPNST cells sensitivity to ripretinib treatment.
Supplementary Figure S3 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: November 2024

Supplementary Figure S3. MPNST cell lines response to trametinib and ripretinib treatment.
Supplementary Figure S2 from MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: November 2024

Supplementary Figure S2. MPNST cell lines response to combination treatment of trametinib and PDGFRα/β inhibitors.
Supplementary Figure S1 from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Authors: Quintela-Fandino Miguel , Bermejo Begoña , Zamora Esther , Moreno Fernando , García-Saenz José Ángel , Pernas Sonia , Martínez-Jañez Noelia , Jiménez Desirée , Adrover Encarna , de Andrés Raquel , Mourón Silvana , Bueno Maria J. , Manso Luis , Viñas Gemma , Alba Emilio , Llombart-Cussac Antonio , Cortés Javier , Tebar Cristina , Roe Denise J. , Grant Adam , Watson Adam , Colomer Ramon , Mouneimne Ghassan
Published: November 2024

EFS in the Luminal A/B tumors subset
Supplementary Figure 5 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
Authors: Stacchiotti Silvia , Martini Silvia , Pasquali Sandro , Frezza Anna M. , Beretta Alessia , Percio Stefano , Lecchi Mara , Tortoreto Monica , Barisella Marta , Collini Paola , Dagrada Gian Paolo , Merlini Alessandra , Huang Paul H. , Jenks Andrew , Jones Robin L. , Tap William D. , Ingrosso Matilde , Morosi Carlo , Brich Silvia , Giani Claudia , Verderio Paolo , Casali Paolo G. , Leonard Hugh , Gronchi Alessandro , Zuco Valentina , Zaffaroni Nadia
Published: November 2024

Supplementary Figure 5. Effect of different siRNA-mediated down-regulation of GDF-15 in EHE cell line.
Supplementary Figure 2 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
Authors: Stacchiotti Silvia , Martini Silvia , Pasquali Sandro , Frezza Anna M. , Beretta Alessia , Percio Stefano , Lecchi Mara , Tortoreto Monica , Barisella Marta , Collini Paola , Dagrada Gian Paolo , Merlini Alessandra , Huang Paul H. , Jenks Andrew , Jones Robin L. , Tap William D. , Ingrosso Matilde , Morosi Carlo , Brich Silvia , Giani Claudia , Verderio Paolo , Casali Paolo G. , Leonard Hugh , Gronchi Alessandro , Zuco Valentina , Zaffaroni Nadia
Published: November 2024

Supplementary Figure 2. CDKN2A loss in EHE clinical tumor and PDX.
Supplementary Table S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Table S3. Univariate analysis of the dynamic (Δ) alteration in the expression levels of genes modulated by treatment.
Supplementary Table S2 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Table S2. Dynamic gene expression between baseline and week 13.
Supplementary Table S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Table S1. Univariate analysis of cell densities.
Supplementary Figure S4 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Figure S4. Correlation between progression-free survival (PFS) and the dynamic alteration in the expression of additional soluble proteins in plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). PFS cut-off was defined as 7.2 months and calculated by MAXSTAT. Significance was defined as p<0.05 and calculated by Wilcoxon paired test. Concentration is represented as log2 (pg/mL).
Supplementary Figure S3 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Figure S3. Dynamic modulation of soluble factors in paired plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). Significance was defined as p<0.05 and calculated by Wilcoxon paired test. Concentration is represented as log2 (pg/mL).
Supplementary Figure S1 from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Supplementary Figure S1. Consort diagram. Number of samples included in the correlative studies of HTG transcriptomics, multiplexed immunoassays and multiplexed immune-phenotyping.
Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Authors: Dallos Matthew C. , Obradovic Aleksandar Z. , McCann Patrick , Chowdhury Nivedita , Pratapa Aditya , Aggen David H. , Gaffney Christopher , Autio Karen A. , Virk Renu K. , De Marzo Angelo M. , Antonarakis Emmanuel S. , Scher Howard I. , Drake Charles G. , Rathkopf Dana E.
Published: November 2024

Supplemental Figure S6. Spatial proximity between immune cells and tumor cells.
Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Authors: Dallos Matthew C. , Obradovic Aleksandar Z. , McCann Patrick , Chowdhury Nivedita , Pratapa Aditya , Aggen David H. , Gaffney Christopher , Autio Karen A. , Virk Renu K. , De Marzo Angelo M. , Antonarakis Emmanuel S. , Scher Howard I. , Drake Charles G. , Rathkopf Dana E.
Published: November 2024

Supplemental Figure S4. GO Activated Immune Response Genes.
Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Authors: Dallos Matthew C. , Obradovic Aleksandar Z. , McCann Patrick , Chowdhury Nivedita , Pratapa Aditya , Aggen David H. , Gaffney Christopher , Autio Karen A. , Virk Renu K. , De Marzo Angelo M. , Antonarakis Emmanuel S. , Scher Howard I. , Drake Charles G. , Rathkopf Dana E.
Published: November 2024

Supplemental Figure S3. Top differentially activated GO pathways with ADT.
Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Authors: Dallos Matthew C. , Obradovic Aleksandar Z. , McCann Patrick , Chowdhury Nivedita , Pratapa Aditya , Aggen David H. , Gaffney Christopher , Autio Karen A. , Virk Renu K. , De Marzo Angelo M. , Antonarakis Emmanuel S. , Scher Howard I. , Drake Charles G. , Rathkopf Dana E.
Published: November 2024

Supplemental Figure S2. Differential expression of androgen-related genes with or without degarelix.
Supplementary Figure S5 from Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer
Authors: Lee Hey Min , Saw Ajay Kumar , Morris Van K. , Napolitano Stefania , Bristow Christopher , Srinivasan Sanjana , Peoples Micheal , Sorokin Alexey , Kanikarla Marie Preeti , Schulz Jonathan , Singh Anand K. , Terranova Christopher , Coker Oluwadara , Jain Abhinav , Kopetz Scott , Rai Kunal
Published: November 2024

Extended investigation of the combination of 5-azacitidine and PRC inhibitors
Supplementary Table S5 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Authors: Rixe Olivier , Villano John L. , Wesolowski Robert , Noonan Anne M. , Puduvalli Vinay K. , Wise-Draper Trisha M. , Curry Richard , Yilmaz Emrullah , Cruze Charlie , Ogretmen Besim , Tapolsky Gilles , Takigiku Ray
Published: November 2024

Supplementary Table S5. Narratives for patients with long-term clinical benefit continuing to receive BXQ-350.
Supplementary Table S4 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Authors: Rixe Olivier , Villano John L. , Wesolowski Robert , Noonan Anne M. , Puduvalli Vinay K. , Wise-Draper Trisha M. , Curry Richard , Yilmaz Emrullah , Cruze Charlie , Ogretmen Besim , Tapolsky Gilles , Takigiku Ray
Published: November 2024

Supplementary Table S4. ADAs among patients with PFS >6, >12, and >24 months.
Supplementary Table S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Authors: Rixe Olivier , Villano John L. , Wesolowski Robert , Noonan Anne M. , Puduvalli Vinay K. , Wise-Draper Trisha M. , Curry Richard , Yilmaz Emrullah , Cruze Charlie , Ogretmen Besim , Tapolsky Gilles , Takigiku Ray
Published: November 2024

Supplementary Table S1. Patient disposition in Parts 1, 2, and 3.
Supplementary Table S7 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Authors: Wang Xin , Kang Xiaozheng , Zhang Ruixiang , Xue Liyan , Xu Jiaqi , Zhao Xiaotian , Ou Qiuxiang , Yu Nuo , Feng Guojie , Li Jiao , Zheng Ziyu , Chen Xiankai , Wang Zhen , Zheng Qingfeng , Li Yong , Qin Jianjun , Bi Nan , Li Yin
Published: November 2024

Supplementary Table 7. Associations of postoperative pathological characteristics with t1 and t2 MRD status
Supplementary Methods S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Authors: Rixe Olivier , Villano John L. , Wesolowski Robert , Noonan Anne M. , Puduvalli Vinay K. , Wise-Draper Trisha M. , Curry Richard , Yilmaz Emrullah , Cruze Charlie , Ogretmen Besim , Tapolsky Gilles , Takigiku Ray
Published: November 2024

Supplementary Methods S1. Dose-limiting toxicity definitions, Treatment administration, Key inclusion criteria, and Key exclusion criteria.
Supplementary Table S6 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Authors: Wang Xin , Kang Xiaozheng , Zhang Ruixiang , Xue Liyan , Xu Jiaqi , Zhao Xiaotian , Ou Qiuxiang , Yu Nuo , Feng Guojie , Li Jiao , Zheng Ziyu , Chen Xiankai , Wang Zhen , Zheng Qingfeng , Li Yong , Qin Jianjun , Bi Nan , Li Yin
Published: November 2024

Supplementary Table 6. Associations of clinical characteristics with t1 and t2 MRD statu
Supplementary Figure S6 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Authors: Wang Xin , Kang Xiaozheng , Zhang Ruixiang , Xue Liyan , Xu Jiaqi , Zhao Xiaotian , Ou Qiuxiang , Yu Nuo , Feng Guojie , Li Jiao , Zheng Ziyu , Chen Xiankai , Wang Zhen , Zheng Qingfeng , Li Yong , Qin Jianjun , Bi Nan , Li Yin
Published: November 2024

Supplementary Figure 6. Results of multivariable Cox regression models
Supplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Authors: Wang Xin , Kang Xiaozheng , Zhang Ruixiang , Xue Liyan , Xu Jiaqi , Zhao Xiaotian , Ou Qiuxiang , Yu Nuo , Feng Guojie , Li Jiao , Zheng Ziyu , Chen Xiankai , Wang Zhen , Zheng Qingfeng , Li Yong , Qin Jianjun , Bi Nan , Li Yin
Published: November 2024

Supplementary Figure 4. Results of univariate analyses for progression-free survival
Supplementary Figure S2 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Authors: Wang Xin , Kang Xiaozheng , Zhang Ruixiang , Xue Liyan , Xu Jiaqi , Zhao Xiaotian , Ou Qiuxiang , Yu Nuo , Feng Guojie , Li Jiao , Zheng Ziyu , Chen Xiankai , Wang Zhen , Zheng Qingfeng , Li Yong , Qin Jianjun , Bi Nan , Li Yin
Published: November 2024

Supplementary Figure 2. The association between PD-L1 expression and survival in patients who received R0 resection (PD-L1 CPS <10 vs. PD-L1 CPS ≥10)
Supplementary Figure S8 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Authors: Soo Ross A. , Dafni Urania , Han Ji-Youn , Cho Byoung Chul , Nadal Ernest , Yeo Chong Ming , Carcereny Enric , de Castro Javier , Sala Maria Angeles , Coate Linda , Provencio Mariano , Britschgi Christian , Vagenknecht Patrick , Dimopoulou Georgia , Kammler Roswitha , Finn Stephen P. , Peters Solange , Stahel Rolf A.
Published: November 2024

Supplementary Figure S8. Progression-free survival by EGFR del19/L858R mutational status at week 9 (N=105) - landmark analysis (post 9-week time).
Supplementary Figure S5 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Authors: Soo Ross A. , Dafni Urania , Han Ji-Youn , Cho Byoung Chul , Nadal Ernest , Yeo Chong Ming , Carcereny Enric , de Castro Javier , Sala Maria Angeles , Coate Linda , Provencio Mariano , Britschgi Christian , Vagenknecht Patrick , Dimopoulou Georgia , Kammler Roswitha , Finn Stephen P. , Peters Solange , Stahel Rolf A.
Published: November 2024

Supplementary Figure S5. Boxplot of EGFR T790M MAF distribution at baseline (N=136), week 9 (N=110) and progression (N=65) by treatment arm.
Supplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Authors: Soo Ross A. , Dafni Urania , Han Ji-Youn , Cho Byoung Chul , Nadal Ernest , Yeo Chong Ming , Carcereny Enric , de Castro Javier , Sala Maria Angeles , Coate Linda , Provencio Mariano , Britschgi Christian , Vagenknecht Patrick , Dimopoulou Georgia , Kammler Roswitha , Finn Stephen P. , Peters Solange , Stahel Rolf A.
Published: November 2024

Supplementary Figure S10. Overall survival by EGFR T790M mutational status at week 9 (N=106) - landmark analysis (post 9-week time).
Supplementary Figure S7 from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

Supplementary Figure S7. Mikrogen recomLine immunoassay test strip.
Supplementary Figure S6 from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

Supplementary Figure S6. EBNA1 IgA detection of IDE2 amino acid substitution constructs by denaturing immunoblot assay in NPC and healthy sera.
Supplementary Figure S5 from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

Supplementary Figure S5. EBNA1 IgA normalized ratios from denaturing immunoblot assay in box-and-whisker plots.
Supplementary Figure S4 from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

Supplementary Figure S4. EBNA1 IgA cumulative sensitivity and specificity plots by time to diagnosis.
Supplementary Figure S1 from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

Supplementary Figure S1. EBNA1 amino acid sequence conservation - B95-8 consensus vs. NPC sequences.
Data from FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
Authors: Fallah Jaleh , Heiss Brian L. , Joeng Hee-Koung , Weinstock Chana , Gao Xin , Pierce William F. , Chukwurah Benjamin , Bhatnagar Vishal , Fiero Mallorie H. , Amiri-Kordestani Laleh , Pazdur Richard , Kluetz Paul G. , Suzman Daniel L.
Published: November 2024

Abstract
On December 14, 2023, the U.S. FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. The FDA granted traditional approval based on LITESPARK-005 (NCT04195750), an open-label, randomized, head-to-head trial of 746 patients with advanced RCC that progressed following treatment with both a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. Patients were randomized (1:1) to receive belzutifan or everolimus. The primary endpoints were progression-free survival (PFS) assessed by blinded independent central review and overall survival. A statistically significant improvement in PFS was demonstrated for belzutifan compared with everolimus [HR = 0.75; 95% confidence interval (CI), 0.63–0.90; one-sided P value = 0.0008]. Kaplan–Meier curves reflected nonproportional hazards with similar median PFS estimates of 5.6 months (95% CI, 3.9–7.0) in the belzutifan arm and 5.6 months (95% CI, 4.8–5.8) in the everolimus arm. Although not reaching full maturity, the overall survival results seemed to show a favorable trend in the belzutifan arm compared with the everolimus arm (HR, 0.88; 95% CI, 0.73–1.07). The confirmed objective response rate by blinded independent central review was 22% and 3.6% in the belzutifan and everolimus arms, respectively. Observed toxicities differed between treatment arms, but drug discontinuations and interruptions due to treatment-emergent adverse events were lower in the belzutifan arm compared with the everolimus arm, and a descriptive analysis of patient-reported symptom and functional outcomes was suggestive of favorable tolerability for belzutifan compared with everolimus.
Data from High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer
Authors: Quintela-Fandino Miguel , Bermejo Begoña , Zamora Esther , Moreno Fernando , García-Saenz José Ángel , Pernas Sonia , Martínez-Jañez Noelia , Jiménez Desirée , Adrover Encarna , de Andrés Raquel , Mourón Silvana , Bueno Maria J. , Manso Luis , Viñas Gemma , Alba Emilio , Llombart-Cussac Antonio , Cortés Javier , Tebar Cristina , Roe Denise J. , Grant Adam , Watson Adam , Colomer Ramon , Mouneimne Ghassan
Published: November 2024

AbstractPurpose:
Tumor progression has been linked to stiffening of the extracellular matrix caused by fibrosis. Cancer cells can be mechanically conditioned by stiff extracellular matrix, exhibiting a 1,004-gene signature [mechanical conditioning (MeCo) score]. Nintedanib has demonstrated antifibrotic activity in idiopathic pulmonary fibrosis. This study explores nintedanib’s antifibrotic effect on breast cancer outcomes.
Experimental Design:
We present long-term follow-up and analysis of a neoadjuvant randomized phase II trial in early HER2-negative breast cancer. Patients (N = 130) underwent a baseline biopsy and received 12 paclitaxel courses alone (control arm) or in combination with nintedanib (experimental arm). The tumor MeCo score was determined by RNA sequencing. The primary aim was to assess nintedanib’s impact on event-free survival based on MeCo scores.
Results:
Follow-up data were retrieved from 111 patients; 75 baseline and 24 post-run-in phase samples were sequenced. After median follow-up of 9.67 years, median event-free survival was not statistically different between arms (P = 0.37). However, in the control arm, high- versus low-MeCo patients had a statistically higher relapse risk: HR = 0.21; P = 0.0075. This risk was corrected by nintedanib in the experimental arm: HR = 0.37; P = 0.16. Nintedanib demonstrated pharmacodynamic engagement, reducing the MeCo score by 25% during the run-in phase (P < 0.01). Patients with low MeCo after run-in had the best long-term prognosis (HR = 0.087; P = 0.03).
Conclusions:
High MeCo is predictive of poor outcomes in HER2-negative early breast cancer, although this risk can be mitigated by nintedanib, which is able to specifically reduce MeCo.
Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier
Published: November 2024

Purpose:
The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.
Experimental Design:
Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients.
Results:
The density of intratumoral CD8+ T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of CD86, CHI3L1, CXCL10, CXCL9, LAG3, and VCAM1 and the decrease in the expression levels of NR4A1. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5–not reached (NR)] versus 17 months (95% confidence interval, 12.0–NR), P = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples.
Conclusions:
Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy.
Data from The Epstein–Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction
Authors: Warner Benjamin E. , Patel Japan , Wang Renwei , Adams-Haduch Jennifer , Gao Yu-Tang , Koh Woon-Puay , Wong Ka Wo , Chiang Alan K.S. , Yuan Jian-Min , Shair Kathy H.Y.
Published: November 2024

AbstractPurpose:
Antibodies to select Epstein–Barr virus proteins can diagnose early-stage nasopharyngeal carcinoma (NPC). We have previously shown that IgA against Epstein–Barr virus nuclear antigen 1 (EBNA1) can predict incident NPC in high- and intermediate-risk cohorts 4 years before diagnosis. Here, we tested EBNA1 variants, with mutants, to define the sequence requirements for an NPC risk assay.
Experimental Design:
Mammalian-expressed constructs were developed to represent EBNA1 variants 487V and 487A, which can differ by ≥15 amino acids in the N- and C-termini. Denatured lysates were evaluated by a refined IgA and IgG immunoblot assay in a case-control study using prediagnostic NPC sera from two independent cohorts in Singapore and Shanghai, the People’s Republic of China.
Results:
At 95% sensitivity, 487V yielded a 94.9% specificity compared with 86.1% for 487A. EBNA1 deleted for the conserved glycine–alanine repeats (GAr) reduced false positives by 22.8%. NPC sera reacted more strongly to the C-terminus than healthy controls, but the C-terminal construct (a.a. 390–641) showed lower specificity (84.8%) than the EBNA1 GAr–deleted construct (92.4%) at 95% sensitivity.
Conclusions:
Although EBNA1 IgA was present in healthy sera, most epitopes localized to the immunodominant GAr. We conclude that a refined EBNA1 antigen deleted for the GAr, but with residues consistently detected in Southeast Asian NPC tumors, is optimized for risk prediction with an extended sojourn time of 7.5 years. Furthermore, distinct EBNA1 serologic profiles enhanced the utility of the EBNA1 IgA assay for risk stratification. This illustrates the importance of serologically relevant EBNA1 sequences for NPC risk prediction and early detection.
Удосконалення методів прогнозування гнійно-запальних ускладнень після видалення зубів
Authors: Бобокалонова Б. Б. , Кульбашна Я. А.
Published: November 2024

Резюме. У статті розглянуто метод діагностики гнійно-запальних ускладнень після видалення зубів, який базується на порівнянні кількості формених елементів у капілярній крові та з комірки видаленого зуба, що дає змогу підвищити точність прогнозування ризиків ускладнень і своєчасно коригувати ведення післяопераційного періоду.
Мета дослідження – удосконалити методи діагностики ризиків гнійно-запальних ускладнень після видалення зубів; проаналізувати попередні результати дослідження.
Матеріали і методи. Досліджено зразки крові 34 пацієнтів (21 жінки та 13 чоловіків) віком від 18 до 65+ років із періодонтитом у різних клінічних стадіях. Порівнювали клітинний склад капілярної крові та крові з комірки видаленого зуба. Зразки крові фарбували за методикою Лейгмана або Май – Грюнвальда, а потім обробляли барвником за Романовським.
Результати досліджень та їх обговорення. При порівняльному аналізі рівнів лейкоцитів у капілярній крові та з комірки зуба в пацієнтів різного віку та статі було виявлено, що у жінок молодої групи (19–29 років) спостерігається суттєва різниця між рівнями лейкоцитів у комірці зуба та капілярній крові, тоді як в чоловіків цієї ж вікової групи суттєвої різниці не було. Серед жінок середньої вікової групи відзначається відсутність значних розбіжностей між рівнями лейкоцитів у крові з комірки та капілярній крові. Подібна тенденція спостерігається у чоловіків цієї вікової групи. У старшій віковій групі серед жінок тенденція до зниження рівня лейкоцитів у капілярній крові, порівняно з молодшими віковими групами, свідчить про загальне ослаблення системної імунної реакції, у той час як у чоловіків цієї ж вікової групи спостерігається характерне підвищення рівня лейкоцитів у капілярній крові, порівняно з кров’ю із комірки, що не відповідає загальним тенденціям, і може свідчити про активну системну відповідь у чоловіків попри не достатньо виражену локальну реакцію.
Висновки. Діагностика ризиків розвитку гнійно-запальних ускладнень після видалення зубів є важливою складовою успішного лікування пацієнта. Результати аналізу даних порівняння показників лейкоцитів у капілярній крові та з комірки видаленого зуба показали відмінності у різних вікових групах та серед представників чоловічої та жіночої статей. Отриманні результати дають підставу розглядати запропонований у дослідженні метод як ефективний в оцінці ризиків гнійно-запальних процесів після видалення зубів.
Патогенетична роль імунних реакцій на пародонтопатогени ротової порожнини в розвитку запальних процесів у хворих на цукровий діабет та оцінка ефективності комплексних і місцевих лікувальних заходів
Authors: Баліцька О. Ю. , Лоза Є. О.
Published: November 2024

Резюме. Запальні процеси у тканинах пародонта є однією із важливих проблем у стоматології, оскільки, незважаючи на значну ефективність сучасної стоматологічної допомоги, кількість хворих, які потребують лікування, залишається значною. Дослідження ефективності комплексного лікування генералізованого пародонтиту в пацієнтів із цукровим діабетом була та залишається предметом досліджень багатьох вітчизняних і зарубіжних науковців.
Мета дослідження – провести клініко-мікробіологічний та імунологічний аналізи патогенетичних факторів розвитку хронічного генералізованого пародонтиту в пацієнтів із цукровим діабетом та дати оцінку ефективності комплексного лікування його з місцевим застосуванням засобів пролонгованої дії.
Матеріали і методи. Проведено аналіз й узагальнення даних сучасних наукових джерел щодо ефективності комплексного лікування генералізованого пародонтиту в пацієнтів із цукровим діабетом.
Результати досліджень та їх обговорення. У результаті наукового пошуку спостерігається посилення патогенного впливу мікрофлори, що розвивається на тлі зниження імунологічної реактивності організму, що призводить до низької ефективності лікування або зменшення тривалості терапевтичного ефекту. Дані обставини диктують необхідність удосконалення способів лікування запальних захворювань пародонта у пацієнтів із цукровим діабетом.
Висновки. Бактеріальна контамінація пародонтопатогенами ротової порожнини хворих на цукровий діабет активує імунний цитокіногенез із розвитком системних і місцевих судинно-тканинних порушень, лікування яких вимагає комплексного патогенетично обґрунтованого підходу. При лікуванні хронічного генералізованого пародонтиту в пацієнтів із цукровим діабетом існує необхідність включати у комплекс лікувальних заходів протимікробні, імуномодулюючі, протизапальні засоби, поєднані із засобами місцевої дії флавоноїдного походження, при постійній корекції глікемії та інсулінорезистентності.
Relação entre fragilidade autorreferida e autocuidado em adultos de meia-idade e pessoas idosas cadastradas em Unidades de Saúde da Família
Authors: Sezko Rayssa Boelter , Alves Aline Martins , Kwiatkoski Marcelo , Martins Tatiana Carvalho Reis , Luchesi Bruna Moretti
Published: November 2024

Objetivo: Avaliar a associação entre a fragilidade e o autocuidado em adultos de meiaidade e pessoas idosas cadastradas em Unidades de Saúde da Família. Métodos: Estudo transversal e quantitativo realizado em 2021, com 213 indivíduos residentes em Três Lagoas, Mato Grosso do Sul, maiores de 45 anos. Os participantes foram avaliados pelo instrumento de avaliação autorreferida de fragilidade e pela Escala de Avaliação da Capacidade de Autocuidado. Modelos de regressão logística foram construídos para a análise dos dados. Resultados: 67,61% dos participantes eram do sexo feminino, com média de 63,10 anos de idade, 54,00% possuíam escolaridade acima de 4 anos, 55,40% tinham companheiro e 55,40% tomavam até dois medicamentos por dia. Com relação à fragilidade, 48,82% eram frágeis e 38,50% pré-frágeis. A média de pontuação na Escala de Avaliação da Capacidade de Autocuidado foi de 57,21. Os indivíduos pré-frágeis e frágeis tiveram, respectivamente, 3,50 (IC95%: 1,28-9,56) e 5,38 (IC95%: 2,00-14,46) vezes mais chance de ter pior autocuidado do que os não frágeis. Conclusão: A fragilidade e a préfragilidade se relacionam diretamente com uma pior capacidade do indivíduo em cuidar de si próprio. Estratégias de educação em saúde visando melhorar a capacidade de autocuidado devem ser desenvolvidas, especialmente direcionadas a pessoas em processo de fragilização e frágeis.
Human Rights in Limbo: A Human Rights Analysis of Religious Freedom Protections in European Asylum Centres
Authors: McDonald Kareem P. A.
Published: November 2024

This article examines the legal protections for religious freedom afforded to non- detained asylum seekers and refugees in European asylum centres, highlighting the gap between theoretical rights and practical implementation. Despite the fundamental right to freedom of religion or belief, asylum seekers often face coercion, verbal and physical attacks, and restrictions on their religious practices within these centres. The absence of regulations or guidelines exacerbates these problems, leaving operators in a legal grey area and the religious freedom rights of asylum seekers in limbo. The article also examines how the privatisation of refugee reception impacts human rights obligations and the dual nature of state responsibilities—both negative and positive—regarding religious freedom. It emphasises the necessity for the implementation of regulations and guidelines to guarantee the enforcement of religious freedom protections, with the objective of safeguarding the religious freedom rights of asylum seekers and refugees in European asylum centres.
On the Axiological Shift in Europe and Its Impact on the European System of Human Rights as Exemplified by the Council of Europe and European Union
Authors: Budziszewska Anita
Published: November 2024

This article investigates shifts in the primary sources of political and axiological discourse in Europe in the area of human rights. Assumed that there may have been two main causes, firstly, the ongoing cultural change in Europe and the departure from the Christian cultural and axiological foundations in Europe, which also affects the interpretation of human rights, is discussed. Secondly, there may perhaps have been progressive change in the source of human rights, and a departure from the concept of human dignity as a universal source of human rights, in the direction of a European cultural interpretation. This change will be shown by reference the Council of Europe and the EU. The theoretical inspiration for this article has been the theory of Christian Reus Smit, who in his own way shows an alternative history to the formation of the structures of the international system, showing that its fragmentation has been taking place around the consolidation of societies (and states) around newly-created rights. Taking this inspiration into account, the article tries to look at Europe through this prism and the European system of human rights protection in relation to the universal one.
Hippology Between Indic and Persianate Textual Traditions: The Śalihotra of Gulbarga
Authors: Speziale Fabrizio , Orthmann Eva
Published: November 2024

This article looks at the translation of Indian sources on horses in the Persianate culture of South Asia. Horses were an essential tool of Muslim armies and their military hegemony in South Asia. In the regional sultanates, local rulers competed in making Indian sources on hippology available in the Persian language. This contribution focuses on the Tarjoma-ye Sālutar (The Translation of Śalihotra, 1407–8), a translation of an Indian text on hippology produced in Gulbarga for Ahmad I Shāh Vali (r. 1422–35). The Tarjoma-ye Sālutar was rendered into Persian by ʿAbdollāh b. Safi via an intermediate translation in a vernacular language made by a local scholar named Durgadāsa. The use of intermediate translations has often been considered a practice that developed at the court of the Mughal emperor Akbar (r. 1556–1605). Yet the method of translation used for the Tarjoma-ye Sālutar shows that this practice goes back to the Sultanate period. This article explores the contents of the book, including sections dealing with omens taken from horses and veterinary medicine. Furthermore, it explores the way translated materials were adapted to render them more suitable for the new Muslim readership.
Ibn Rushd’s Middle Commentary on the Poetics, or the Ethical Education
Authors: Woerther Frédérique
Published: November 2024

In his Talkhīṣ Kitāb Arisṭūṭālīs fī l-Shiʿr (“Middle Commentary on Aristotle’s Poetics”) Ibn Rushd (Averroes, d. 595/1198) strictly defines poetic statements (al-aqāwīl al-shiʿriyya) as imaginative (mutakhayyila) statements that imitate the good and the evil, and aim at inciting people to virtue and deterring them from vice. Yet the traces of the Aristotelian ethical doctrine in this Commentary are not restricted to this link to virtue ethics, as the entire text follows at different levels the division between virtue/vice and good/evil. Ibn Rushd also refers to the teaching of ethics when discussing the object of poetic imitation (al-tashbīh wa-l-muḥākāt), the different natures he distinguishes among poets, and the genres of panegyric (madīḥ) and satire (hijāʾ). However, recent scholarship tends to view the Poetics in the Islamic context as a fundamentally logical treatise. Following the Alexandrian tradition, the falāsifa sought, at least since al-Fārābī (d. 339/950), to justify and explain the position of the Poetics in the Organon by defining, for example, the logical and psychological mechanisms of the poetical syllogism. More specifically, philosophers drew parallels between the role of imagination (takhayyul) in the poetical context and the role of assent or conviction (taṣdīq) in the other logical arts, and in particular in the Rhetoric (al-Khiṭāba).

The purpose of this contribution is to demonstrate that the Poetics, according to Ibn Rushd, is a treatise that combines logic and ethics and determines in that respect the conditions and the rules of a practical education of the citizens. Like the rhetoric whose political value was already determined, poetics also plays a role in defining the nature and the content of the poetical statements that are to be employed in order to encourage people to virtuous actions – that is, the very condition for a virtuous political, and thus, a happy life. Straddling between logic and ethics, poetry is therefore fundamentally political.
On Divination in the Xunzi and Beyond: A Brief Note with Implications for the Modern Couplings of Secular vs. Sacred, the Personal vs. the Communal, and Monarchical and Autocratic
Authors: Nylan Michael
Published: November 2024

Human beings’ brains are hardwired to see the world in binaries, such as “rational” vs. “superstitious” or “credulous,” “secular” vs. “sacred,” and in concept clusters, such as “monarchical” and “autocratic.” This essay argues that many binaries we have applied to divination theories and practices in the early empires in China contradict the worldviews expressed in the texts from that period, which presumed an extended community composed of the living and the dead over multiple generations, rather than individual lifespans that end with death. In addition, like Aristotle but unlike most moderns, they did not regard all monarchies as autocratic.
The Tricks of Jing (Jing jue 荆決): The Beginnings of jue 決/訣 as an Epistemic Genre
Authors: Cook Constance A.
Published: November 2024

The Chinese genre of text named jue 訣 dates back to the Han dynasty. It encompassed esoteric Daoist manuals and medical handbooks, translated as “tricks,” “methods,” “instructions,” “secret instructions,” and “rhymes.” This essay translates “tricks” and “secrets” for its early use, referring to “writings” (shu 書) linked to privately transmitted technical information, such as divination tricks, alchemical techniques, or medical recipes. Initially, these writings relied on oral instructions and implicit knowledge (“orally transmitted secrets,” koujue 口訣). By the medieval period, as seen in the Dunhuang manuscripts, the link to exclusive oral instruction had weakened, and the jue genre evolved into “how-to” (hezhi 何知) manuals for quick reference in a broader body of formally transmitted texts, like “canons, scriptures” (jing 經). The jue genre began as rhematic (rather than thematic), specifying techniques or “methods” (fa 法), whether Daoist, medical, or divinatory.
An Extreme Predecessor Rain Event in Central China Amplified by Upper-Level Jet Streak
Authors: Rao Chenhong , Chen Guanghua , Ran Lingkun
Published: November 2024

A comprehensive study is conducted on a predecessor rain event (PRE) closely associated with the upper-level jet (ULJ) in central China during July 2021, utilizing the Weather Research and Forecasting (WRF) Model. The ULJ and precipitation patterns are reasonably reproduced in the control experiment. In the sensitivity experiment (NOULJ), the ULJ is largely suppressed by the piecewise potential vorticity inversion method. The comparison of the two simulations indicates that the ULJ promotes the development of secondary circulation, lower-level jet (LLJ), moisture transport, and atmospheric instability. Synergistic effects among these processes amplify this PRE. The strong updrafts in the precipitation region are closely associated with the inverse secondary circulation that develops on the south side of ULJ entrance. The upper-level mass divergence associated with the ULJ enhances the lower-level convergence, promoting the development of lower-level vorticity and LLJ. The LLJ facilitates moisture transport into the precipitation region and increasing atmospheric instability. In contrast, the precipitation in NOULJ is decreased by 34% due to the weakening of favorable conditions.
Bibliometric analysis of social work in the COVID-19 pandemic
Authors: Duru Serdarhan
Published: November 2024

This bibliometric analysis examined 1435 social work articles on COVID-19 from 2019 to 2024. The most prolific journal was International Social Work, and the University of Texas System led in productivity. The United States of America had the most publications and citations. Social work journals interacted with public health, medicine, and psychiatry.
Consequences of forced conjunction: Social work’s struggles for independence from sociology in mainland China
Authors: Fu Linyun , Wu Shiyou , Kang Xixi
Published: November 2024

This article critically reviews the relationship between social work and sociology in mainland China, focusing on the reconstruction period from 1988 to the present. The forced conjunction of social work and sociology, initiated by governments and sociologists, has created significant barriers for social work education, research, and practice. Given the proliferation of the field of social work in mainland China, and sociology’s substantial influence on social work, this article emphasizes the crucialness of discipline autonomy of social work and sheds lights on potential solutions including strengthening social work practices at multiple levels and making efforts in promoting social work science.